Premium
Elevated soluble intercellular adhesion molecules‐1 in inflammatory myopathy
Author(s) -
Kumamoto T.,
Abe T.,
Ueyama H.,
Sugihara R.,
Shigenaga T.,
Tsuda T.
Publication year - 1997
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1997.tb00065.x
Subject(s) - polymyositis , dermatomyositis , inflammatory myopathy , medicine , myopathy , intercellular adhesion molecule 1 , cell adhesion molecule , inflammation , immunology , gastroenterology , pathophysiology
– We evaluated the serum level of soluble intercellular adhesion molecule‐1 (sICAM‐1) in patients with polymyositis (PM) and dermatomyositis (DM) and investigated the correlation between the serum level of sICAM‐1 and clinical findings. Material and methods – We measured the serum level of sICAM‐1 using an enzyme‐linked immunosorbent assay in 19 untreated patients with inflammatory myopathy (14 patients with PM and 5 patients with DM), 20 patients with other neuromuscular disorders in which immunological mechanisms are unlikely to be involved, and 14 normal healthy controls. Results – The serum level of sICAM‐1 was significantly higher in patients with PM/DM compared with patients with other neurological disorders and control subjects. The sICAM‐1 level was, however, not correlated with the clinical characteristic including disease severity, the duration of illness, and the serum level of CK. Conclusion – These findings suggest that sICAM‐1 is involved in the inflammatory process of PM and DM.